Wenzhou Celecare Medical Instruments Co.,Ltd , https://www.wzcelecare.com
Fighting for the $1.2 billion market, Hisun Pharmaceuticals Losartan Potassium Tablets were approved in the US
Medical Network April 12, April 10, Haizheng Pharmaceutical announced that its holding subsidiary Haizheng Pharmaceutical (Hangzhou) Co., Ltd. (hereinafter referred to as "Haizheng Hangzhou Company") received the US Food and Drug Administration ( The following is the notification of the “US FDAâ€. The application for the new drug of Losartan potassium tablets submitted by Haizheng Hangzhou Company to the US FDA (ANDA, the US generic drug application, the application for US FDA review approval means that the applicant can produce And the product is sold in the US market) has been approved.
Losartan potassium tablets are mainly used for the treatment of hypertension and type 2 diabetic nephropathy. The original research drug Cozaar was developed by Merck. The domestic and foreign manufacturers mainly include Zhejiang Huahai Pharmaceutical Co., Ltd., China Resources Shuanghe Pharmaceutical Co., Ltd. and Beijing Shuangji Pharmaceutical Co., Ltd.
According to statistics, Losartan potassium tablets (25mg, 50mg, 100mg) in 2017 global sales of about 154,185,700 US dollars, of which the US market sales of about 98,784,400 US dollars; 2018 global sales of about 1,423,503,600 US dollars, of which the US market sales Approximately $11,586,900 (data from IMS).
Up to now, Hisun Pharmaceutical has invested about 6.8 million yuan in the drug research and development project. The approval of the FDA approval of the Losartan potassium tablet ANDA marks the company's eligibility to sell the product in the US market and has a positive impact on the company's expansion into the US market.